5 Key Takeaways

• 1

  Pharmaceutical supply chains face renewed pressure from geopolitical instability, including the Iran conflict and the war in Ukraine.

• 2

  Only 22% of life sciences firms are preparing for supply chain disruptions, despite 62% feeling pressure to reduce operational costs.

• 3

  Medicines requiring refrigeration, such as biologics and vaccines, are particularly vulnerable to geopolitical disruptions affecting transport.

• 4

  Energy market disruptions due to geopolitical instability can increase pharmaceutical manufacturing costs and affect medicine availability.

• 5

  Companies must adopt strategic supply chain designs, including dual sourcing and increased safety stock, to enhance resilience.